Evidence map›Paper›PMID 21882941›Full record

ArticleFuture medicinal chemistry2011

Marine natural products: a new wave of drugs?

Rana Montaser, Hendrik Luesch

Open access · greenAbstract read
In one paragraph

Article in Future medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed, 1 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

172 citing papers in PubMed, 1 synthesis or guideline pooled it, 421 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. The Ubiquitin-Proteasome System in Brain Disorders: Pathogenic Pathways, Post-Translational Tweaks, and Therapeutic Frontiers.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

112 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rana MontaserDepartment of Medicinal Chemistry, University of Florida, Gainesville, FL 32610, USA.
Hendrik Luesch
University of Florida · US

Funding

Chemistry and Biology of LargazolesR01CA138544 · NCI · UNIVERSITY OF FLORIDA · PI HONG, JIYONG, LUESCH, HENDRIK · 2009 to 2012
$1.2M
Pilot-Scale Libraries of Marine Cyanobacterial Natural ProductsP41GM086210 · NIGMS · UNIVERSITY OF FLORIDA · PI LUESCH, HENDRIK, PAUL, VALERIE JEAN · 2008 to 2010
$1.2M
Activation of the Cancer Preventive Nrf2-ARE Pathway by SeaweedR21CA133681 · NCI · UNIVERSITY OF FLORIDA · PI LUESCH, HENDRIK · 2008 to 2009
$357k
NCI NIH HHS R01 CA138544NCI NIH HHS R01CA138544NCI NIH HHS R21 CA133681NCI NIH HHS R21CA133681NIGMS NIH HHS P41 GM086210NIGMS NIH HHS P41GM806210
6 · The paper itself

Abstract

The largely unexplored marine world that presumably harbors the most biodiversity may be the vastest resource to discover novel 'validated' structures with novel modes of action that cover biologically relevant chemical space. Several challenges, including the supply problem and target identification, need to be met for successful drug development of these often complex molecules; however, approaches are available to overcome the hurdles. Advances in technologies such as sampling strategies, nanoscale NMR for structure determination, total chemical synthesis, fermentation and biotechnology are all crucial to the success of marine natural products as drug leads. We illustrate the high degree of innovation in the field of marine natural products, which in our view will lead to a new wave of drugs that flow into the market and pharmacies in the future.

Indexed as

Aquatic OrganismsBiodiversityBiological ProductsBiotechnologyClinical Trials as TopicDrug Evaluation, PreclinicalFermentationPharmaceutical PreparationsStructure-Activity RelationshipBiological ProductsPharmaceutical Preparations

Identifiers

PMID21882941
PMCPMC3210699
OpenAlexW2032889069

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.